ArticlePulmonary circulation2026
Long-Term Subcutaneous Treprostinil in Pediatric Pulmonary Arterial Hypertension at a Latin American Referral Center: A Retrospective Cohort Study.
Article in Pulmonary circulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric pulmonary arterial hypertension is a progressive vasculopathy with substantial early mortality. Subcutaneous treprostinil is an established prostacyclin-pathway therapy for higher-risk disease, but long-term pediatric data from Latin American referral centers remain limited. This retrospective cohort included all nine consecutive children with World Symposium on Pulmonary Hypertension Group 1 pulmonary arterial hypertension who initiated subcutaneous treprostinil at a Colombian referral center and were followed from diagnosis until death or last known contact. Outcomes included survival, pediatric risk category transitions, N-terminal pro-B-type natriuretic peptide levels, tricuspid annular plane systolic excursion, systolic pulmonary artery pressure, eccentricity index, and structured patient-/caregiver-reported domains. Exploratory comparisons were performed by maintenance dose (≤ 60 vs. > 60 ng/kg/min) and therapy duration. Kaplan-Meier survival at 1, 3, and 5 years was 88.9%, 55.6%, and 55.6%, respectively. Eccentricity index decreased from a median of 2.8 at diagnosis to 1.5 at 5 years, with paired comparisons showing reductions at 1 and 3 years. By Year 5, four of five children with paired risk data had transitioned to a lower pediatric risk category. Doses > 60 ng/kg/min were associated descriptively with more favorable final risk profiles, whereas structured patient-/caregiver-reported domains showed heterogeneous patterns; schooling was the only domain with a statistically detectable association by both dose and duration. In this small Latin American referral-center cohort, subcutaneous treprostinil treatment was accompanied by favorable risk transitions and stabilization of right ventricular geometry among long-term survivors. These findings are exploratory and should be interpreted in light of the small sample size, retrospective design, missing longitudinal data, and potential confounding by disease severity, survival, and treatment escalation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.